Layered Peptide Arrays (often referred to in the published scientific literature as “Layered Expression Scanning” or “LES”) is a pioneering, highly innovative technology that is expected to have a dramatic impact on personalized medicine. The technology is being developed by two teams at the NIH National Cancer Institute: one with the Tissue Array Research Program and the other team part of the Laboratory of Pathology. Both have support from 20/20 under a Cooperative Research and Development Agreement (CRADA). Our company has exclusive rights under all patents relating to this proprietary technology. In short, specially constructed bioaffinity (“smart”) membranes are stacked and applied to various 2-D samples such as tissue sections, multi-well plates, and electrophoresis gels. Two versions of the platform are currently employed (click on images for detail). The methodology is described in a 2007 review. These arrays permits multiple proteins to be identified in tumors and other tissues while maintaining the shape and morphology of the tissue. Layered Peptide Arrays have exciting applications in diagnostics and molecular pathology.